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Fluorescence lifetime imaging microscopy (FLIM) and single-molecule super-resolution microscopy (SRM) illustrate the 
intracellular fate of Sn-2 phosphatidylcholine prodrugs.  
Abstract 
While the in vivo efficacy of Sn-2 phosphatidylcholine prodrugs incorporated into targeted, non-
pegylated lipid-encapsulated nanoparticles was demonstrated in prior preclinical studies, the 
microscopic details of cell prodrug internalization and trafficking events are unknown. Classic 
fluorescence microscopy, fluorescence lifetime imaging microscopy, and single-molecule super-
resolution microscopy were used to investigate the cellular handling of doxorubicin-prodrug and 
AlexaFluorÔ-488-prodrug. Sn-2 phosphatidylcholine prodrugs delivered by hemifusion of 
nanoparticle and cell phospholipid membranes functioned as phosphatidylcholine mimics, 
circumventing the challenges of endosome sequestration and release. Phosphatidylcholine prodrugs in 
the outer cell membrane leaflet translocated to the inner membrane leaflet by ATP-dependent and ATP-
independent mechanisms and distributed broadly within the cytosolic membranes over the next 12 h.  
A portion of the phosphatidylcholine prodrug populated vesicle membranes trafficked to the perinuclear 
Golgi/ER region, where the drug was enzymatically liberated and activated.  Native doxorubicin entered 
the cells, passed rapidly to the nucleus, and bound to dsDNA, whereas DOX was first enzymatically 
liberated from DOX-prodrug within the cytosol, particularly in the perinuclear region, before binding 
nuclear dsDNA. Much of DOX-prodrug was initially retained within intracellular membranes. In vitro 
anti-proliferation effectiveness of the two drug delivery approaches was equivalent at 48 h, suggesting 
that residual intracellular DOX-prodrug may constitute a slow-release drug reservoir that enhances 
effectiveness. We have demonstrated that Sn-2 phosphatidylcholine prodrugs function as 
phosphatidylcholine mimics following reported pathways of phosphatidylcholine distribution and 
metabolism. Drug complexed to the Sn-2 fatty acid is enzymatically liberated and reactivated over many 
hours, which may enhance efficacy over time. 
Keywords:  
Phosphatidylcholine prodrugs, Nanomedicine, Fluorescence lifetime imaging microscopy, Super-
resolution microscopy 
Abbreviations: 
• AF488 AlexaFluorÔ 488 
• API active pharmaceutical ingredient 
• αvβ3 alpha v beta 3 integrin  
• CFDD Contact Facilitated Drug Delivery  
• cPLA2 cytosolic phospholipase A2  
• DAPI 4',6-Diamidino-2-phenylindole, dihydrochloride  
• DMEM Dulbecco's Modified Eagle’s Medium  
• dsDNA double-stranded deoxyribonucleic acid  
• ER endoplasmic reticulum  
• FLIM fluorescence lifetime imaging microscopy  
• MC540 merocyanine 540  
• PAINT Point Accumulation for Imaging in Nanoscale Topography  
• Paz-PC 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine" 
• PC phosphatidylcholine 
• PD prodrug  
• PFOB  perfluoro-1-bromooctane  
• PE  phosphatidylethanolamine  
• PE-PTX  phosphatidylethanolamine-paclitaxel 
• PLA  phospholipase  
• SRM  super-resolution microscopy  
• Sn-2  stereospecific numbering position 2  
• τamp  amplitude average lifetime  
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Rationale and purpose 
Sn-2 phosphatidylcholine prodrugs in non-
pegylated lipid nanoparticle membranes are 
known to be resistant to premature release and 
metabolism in circulation. This approach using 
targeted drug delivery has been demonstrated to 
be effective in a variety of preclinical models. 
Cellular uptake of these compounds is 
hypothesized to be secondary to a hemifusion 
contact-facilitated drug delivery mechanism 
with cytosolic enzymatic drug release, which 
circumvents sequestration in the endosome-
lysosome pathway. This research utilized 
advanced complementary optical imaging 
methods, including confocal fluorescence 
lifetime and super-resolution single molecule 
microscopy, to elucidate and compare PC 
prodrug cellular trafficking and metabolism 
with previously known paths of natural PC.   
Introduction 
The concept of achieving Paul Erhlich’s 
inspired vision of a “magic bullet” to treat 
disease remains challenging in the context of 
nanomedicine. While specific reasons vary 
among nanosystems, in general, early systemic 
drug loss, low net drug delivery to targeted 
cells, and  limited free drug intracellular 
bioavailability have been major barriers [1].  
Very hydrophobic drugs, such as fumagillin, 
incorporated into the phosphatidylcholine-
based surfactant membranes of αvβ3-targeted 
nanosized emulsion particles [2-7] provided 
anti-angiogenic benefits that were broadly 
demonstrated in vitro and in vivo by imaging, 
microscopy, and functional outcomes [3, 6-8]. 
Hydrophobic drugs dissolved into the lipid 
surfactant spontaneously transferred to targeted 
cell membranes through an irreversible 
hemifusion process referred to as contact-
facilitated drug delivery (CFDD) [2, 4]. Despite 
in vivo effectiveness, the pharmacokinetics of 
the drug relative to the other lipid surfactant 
components and the perfluorocarbon (PFC) 
core were discrepant and showed marked 
premature fumagillin loss during circulation 
[9]. Lipid-anchored homing ligands and 
gadolinium chelates co-incorporated into the 
surfactant of PFC nanoparticles (NP) had 
similar pharmacokinetic clearance rates as a 
percentage of injected dose in rodents. Less 
hydrophobic drugs dissolved into the lipid 
surfactant, such as paclitaxel or doxorubicin, 
had rapid circulatory clearance rates compared 
to the PFC NP core and other membrane 
constituents. The very poor particle retention of 
these drugs accounted for their lack of efficacy 
in cancer models when studied in vivo [10].   
In an earlier report, rhodamine-PE was 
employed as a fluorescent drug surrogate to 
illustrate and elucidate the CFDD mechanism. 
Rhodamine-PE delivered with integrin-targeted 
PFC NP integrated into the cell membrane upon 
binding and readily passed via lipid rafts into C-
32 human melanoma cells at 37°C [4]. In 
contradistinction to rhodamine-PE, paclitaxel 
conjugated to phosphatidylethanolamine failed 
to translocate from the outer to inner cell 
membrane leaflets. The concept of chemically 
coupling drugs to the Sn-2 fatty acid of 
phosphatidylcholine (PC) was envisioned as an 
alternative approach to facilitate nanoparticle 
drug retention during circulation, to protect 
chemically-sensitive compounds from 
interactions with blood constituents, and to 
transfer into the targeted cell via CFDD.  In vivo 
studies demonstrated that the Sn-2 prodrug 
motif was efficacious for fumagillin, docetaxel, 
and recently cMYC-inhibitors [9-12]. 
While the concept of Sn-2 phospholipid 
prodrugs was never considered for ligand-
targeted drug delivery in association with the 
CFDD hemifusion mechanism, precedence for 
Sn-2 phospholipid prodrugs was found to exist, 
initially reported by David Thompson et al.  in 
the context of triggered drug release 
mechanisms [13].  Later, Andresen and 
colleagues [14-24] pursued an approach to 
deliver chemotherapeutics as Sn-2 prodrugs via 
untargeted liposomes, anticipating that 
phospholipases liberated locally by cancers 
would trigger local drug release.  Their 
hypothesis was essentially incorrect. Physical-
chemical modeling by this team revealed that 
non-pegylated liposomes were resistant to free 
water penetration and premature hydrolysis of 
the synthetic ether-lipid prodrugs. However, 
pegylation of liposomes, a design feature 
commonly employed to extend circulatory half-
life, wicked water into the membrane creating 
access to lipases with resultant rapid premature 
drug release. 
Phosphatidylcholine (PC) populates all cell 
and intracellular membranes in contrast to 
phosphatidylethanolamine or 
phosphatidylserine, which preferentially reside 
in the inner cell membrane leaflet and other 
specific organelles, such as the mitochondria 
[25, 26]. The Sn-2 PC prodrug motif was 
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adopted as a PC mimic that would circumvent 
endosomal NP internalization and resultant 
losses by intercalation into the cell membrane 
and trafficking throughout the intracellular 
membranes until lipases, such as phospholipase 
A2, liberated a bioactive drug.  However, this 
working hypothesis for the effectiveness of Sn-
2 PC prodrug has never been elucidated. 
 In the present study, complementary 
microscopic imaging techniques were utilized 
to explore cell membrane uptake, cellular 
internalization and intracellular distribution of 
a doxorubicin Sn-2 PC prodrug or 
AlexaFluor™ Sn-2 PC prodrug.  The objectives 
were to compare the biopotency of a 
phosphatidylcholine doxorubicin prodrug 
(DOX-PD) with free doxorubicin (DOX) and to 
utilize fluorescence lifetime imaging 
microscopy (FLIM) to compare the trafficking 
of DOX-PD versus free DOX from the outer 
cell membrane to the nucleus.  To corroborate 
and extend the FLIM results, single-molecule 
super-resolution optical microscopy [27-29] 
was employed to map Sn-2 AlexaFluorÔ 488 
prodrug (AF488-PD) trajectories from the cell 
membrane uptake, outer to inner membrane 
leaflet transfer, and throughout the intracellular 
membranes. 
Experimental design 
 The present study employed traditional 
fluorescence microscopy, confocal 
fluorescence lifetime imaging microscopy 
(FLIM), and single molecule super-resolution 
optical microscopy in a complementary fashion 
to track optically active Sn-2 
phosphatidylcholine prodrug in normal and 
cancerous cells. The experimental protocols 
utilized a doxorubicin prodrug for fluorescence 
microscopy and confocal fluorescence lifetime 
imaging for assessments of the cell membrane, 
cytosol, and nucleus. A more photostable dye, 
AlexaFluor™ 488, was synthesized into an Sn-
2 prodrug motif to detect single prodrug 
molecules in the presence of autofluorescence. 
This enhanced photostability extended the 
SRM tracking time and permitted better 
estimates of molecular migration patterns and 
prodrug membrane retention. 
Fluorescence microscopy differentiated free 
DOX and DOX-PD distribution from the outer 
cell membrane, cytoplasm and nucleus. FLIM, 
which assessed distributions between local 
biochemical environments based on changes in 
excited-state lifetimes, offered qualitative 
discrimination between drug retained in cell 
membranes, enzymatically released into the 
cytosol, or in the nucleus bound to dsDNA. 
Super-resolution optical microscopy 
dynamically tracked single prodrug (AF488-
PD) molecules across multiple focal planes, 
demonstrating spatial uptake, translocation and 
distribution within the cell until the dye was 
enzymatically liberated, after which rapid 
molecular motion beyond the confocal volume 
precluded detection. Collectively, these 
observations and measurements demonstrate 
the CFDD drug delivery mechanism of PC 
prodrugs and the avoidance of endosomal 
sequestration and degradation. 
Materials and methods 
Synthesis and characterization of 
doxorubicin and AlexaFluorÔ 488 
prodrugs 
 Doxorubicin Sn-2 prodrug conjugates 
(DOX-PD) were synthesized in our laboratory 
starting from commercially available 
doxorubicin (Sigma Aldrich, St. Louis, MO) 
and oxidized phospholipids (NOF America, 
White Plains, NY).  In this approach, 
doxorubicin (0.22 mM) was dissolved in 
dimethylsulfoxide (DMSO) and triethylamine 
(1 mM). Added to this solution was (S)-2-(8-
carboxyoctanoyloxy)-3-(palmitoyloxy)propyl 
2-(trimethylammonio) ethyl phosphate 
(PAzPC, 0.2 mM, NOF America) dissolved in 
chloroform with cyclohexylcarbodiimide (1 
mM).   The reagent mixture was shaken 
overnight at room temperature (RT) then 
purified using silica gel column 
chromatography. The desired product DOX-PD 
was characterized using mass spectroscopy: 
Chemical Formula: C60H91N2O20P, ESI-MS 
M+H+ Cal. 1190.63, exp.1191.6 (Shimadzu 
LCMS 2010A, Kyoto, Japan) (Figure S1). 
 The AlexaFluorÔ 488 Sn-2 
phospholipid conjugate (AF488-PD) was 
synthesized from commercially available 
AlexaFluorÔ 488 (Thermo Fisher Scientific, 
Waltham, MA) and oxidized 
phosphatidylcholine (NOF America, PAzPC). 
In this approach, AlexaFluorÔ 488 cadaverine 
(1.56 µmoles in 1 mL dimethylformamide) was 
combined with excess PAzPC (6.6 µmole) 
dissolved in 2 mL chloroform to which 
triethylamine (50 µl) and N,N’-
diisopropylcarbodiimide (50 µL) were added. 
The mixture was reacted for 2-3 hours. 
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Separation with silica TLC (0.2M 
NH4Ac:MeOH:water - 20:100:200) revealed 
only the conjugated dye (RF 0); the free dye 
control was seen at RF ~ 0.8. The sample was 
dialyzed (MWCO 500-1000) then lyophilized. 
Purified AF488-PD was characterized using 
mass spectroscopy: final chemical formula was 
C74H113N7NaO23PS2+2H+, ESI-MS M+H+ Cal. 
793, exp.793.85 (Shimadzu LCMS 2010A, 
Kyoto, Japan) (Figure S1).  
Synthesis and characterization of αvβ3 
DOX-PD PFOB nanoparticles 
Nanoparticles (NP) were prepared as a 
microfluidized suspension of 20% (v/v) 
perfluoro-1-bromooctane (PFOB, Exfluor 
Research Corporation, TX), 2.0% (w/v) of a 
surfactant co-mixture and 1.7% (w/v) glycerin 
in Milli-Q® water. An αvβ3-integrin antagonist, 
a quinolone nonpeptide developed by Bristol-
Myers Squibb Medical Imaging (US patent US 
6511648 and related patents) was used for 
homing (a gift, Kereos, Inc., St. Louis, MO). 
The surfactant co-mixture included: 
approximately 97.6 mole% lecithin, 0.15 
mole% of αvβ3-ligand-conjugated lipid and 2.28 
mole% of DOX-PD (0.5 mM).  The surfactant 
components were combined with the PFOB, 
buffer and glycerine and Milli-Q® water, then 
the mixture was homogenized at 20000 psi for 
4 min. The NP were preserved under inert gas 
in sterile sealed vials until use. Nominal αvβ3-
DOX-PD PFOB NP and size by dynamic light 
scattering was 260 nm, with a polydispersity of 
0.14 and zeta potential of -7.4 mV. The 
surfactants of fluorescent PFOB NP 
incorporated 0.1 mol% rhodamine-
phosphatidylethanolamine (Avanti Polar 
Lipids, Alabaster, AL) or 0.1 mol% AF488-PD 
in the lipid commixture at the expense of 
phosphatidylcholine. 
Absorption and fluorescence 
spectroscopy  
DOX and DOX-PD were used for absorption 
and fluorescence spectroscopy. The materials 
were diluted in Milli-Q® water. Absorption 
spectra were measured on a DU 640 
spectrophotometer (Beckman-Coulter, Brea, 
CA). Fluorescence emission spectra were 
recorded on a FluoroLog 3 spectrofluorometer 
(Horiba Jobin Yvon, Edison, NJ) using 585 
nm/600-700 nm as excitation/emission 
wavelength with 5 nm slits.  
Cell culture 
For fluorescence microscopy, 2F2B mouse 
endothelial cells (ATCC CRL2168, Manassas, 
VA, USA) were cultured in Dulbecco's 
modified Eagle's medium (DMEM, no phenol 
red, Gibco, Thermo Fisher Scientific, Waltham, 
MA) with 4.5 g/L glucose and 10% heat 
inactivated fetal bovine serum.  Cells were 
plated on sterile 12 mm cover glasses (#1.5) in 
a 24 well plate at approximately 1x105 cells per 
well and incubated overnight at 37 °C in a 5% 
CO2 incubator. Doxorubicin (Sigma, St Louis, 
MO, USA) or αvβ3-DOX-PD PFOB NPs were 
added to the cells at a final concentration of 3 
µM active drug in complete media.  After 1 h, 
the cells were washed three times in PBS and 
fixed in 4% paraformaldehyde solution for 30 
min.  The coverslips were rinsed in PBS; the 
cell nuclei were stained blue with DAPI (4',6-
diamidino-2-phenylindole, dihydrochloride); 
and samples were analyzed by fluorescence 
microscopy (Olympus BX61, Shinjuku, Tokyo, 
Japan). 
For confocal fluorescence lifetime imaging 
microscopy, human C-32 melanoma cells 
(Washington University Tissue Culture 
Support Center, St. Louis, MO) were cultured 
in Minimal Essential Media containing Earle’s 
salts (no phenol red, Gibco, Thermo Fisher 
Scientific, Waltham, MA) and supplemented 
with 10% (v/v) fetal bovine serum (Sigma-
Aldrich, St. Louis, MO),  1% penicillin and 1% 
streptomycin (Gibco).  The cells were 
trypsinized and plated on glass bottom dishes 
(35 mm, glass #1, MatTek Corporation, 
Ashland, MA) and grown overnight in phenol 
red-free media. The drug formulations were 
diluted in the culture media and cells were 
incubated for varying times. After incubation 
and washing, fluorescence lifetime imaging 
was performed on live cells in a humidified 
stage-top incubator with 5% CO2. 
For super-resolution imaging, 2F2B mouse 
endothelial cells were cultured in DMEM with 
10% fetal bovine serum (Gibco) plus 1% 
penicillin and 1% streptomycin (Gibco) and 
incubated at 37ºC with 5% CO2.  2F2B cells 
were trypsinized and plated on ozone-
pretreated high-tolerance coverslips (No. 1.5, 
170 ± 5 μm thickness, Azer Scientific, 
Morgantown, PA), and incubated for 48 h. The 
cells were further treated with 1.6 μg/mL 
AF488-PD at 37 ºC for 12 h, or 0.05 μg/mL 
AF488-PD at room temperature for 5 min 
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before imaging. The 2F2B cells were also 
treated with 1.4 μM PE-rhodamine at 37 ºC for 
1 h and rinsed with PBS for standard 
epifluorescence imaging. 
Cytotoxicity assay  
 The retained cytotoxicity of DOX-PD 
was compared to native DOX in mouse 
endothelial cells. 2F2B cells were seeded on a 
96 well plate (2000-5000 cells/well) in DMEM 
with 10% heat-inactivated fetal bovine serum 
plus 10 µM angiotensin II (Sigma-Aldrich, St. 
Louis, MO) then incubated at 37 ºC with 5% 
CO2. After 24 h, cells were incubated for 1 h 
with a) αvβ3-DOX-PD PFOB NP (0.3 µM DOX 
PD), b) equimolar equivalent of native 
doxorubicin HCl or c) αvβ3-No drug NP. After 
incubation the wells were washed three times 
with PBS and returned to the incubator for 48 
h. Cell proliferation was measured using the 
MTT assay for cytotoxicity, which measures 
the activity of cellular enzymes that reduce the 
tetrazolium dye to the insoluble formazan 
(Invitrogen; Thermo-Fisher Scientific, 
Waltham, MA). Each treatment was replicated 
6 times. 
Fluorescence lifetime spectroscopy, 
imaging and data analysis 
Confocal fluorescence lifetime spectroscopy 
and imaging was performed with a MicroTime 
200 microscope (Picoquant, Berlin, Germany). 
For spectroscopy, fluorescence lifetimes of 
DOX (50 µM) and DOX-PD (50 µM) solutions 
in MilliQ® water (final DMSO 0.5%) were 
measured under a 100X oil immersion 
objective with 485 nm (15 au) laser excitation 
pulsed at 40 MHz. Decay data were collected 
through a 519 nm long pass filter and 
accumulated until peak photon counts reached 
10,000. Almost identical conditions were 
applied for αvβ3-DOX-PD PFOB NPs (25 µM 
doxorubicin concentration) except the pulse 
rate was reduced to 20 MHz in order to capture 
its slower decay. Live cell imaging utilized 485 
nm laser excitation (~1000 au) at 20 MHz on 
cells maintained in a stage top CO2 incubator 
for the period of imaging.   
Lifetime decay data collected from 
spectroscopy and microscopic imaging were 
analyzed on the SymphoTime software 
(Picoquant, Berlin, Germany).  All decays were 
fit using multi-exponential tail fit using the 
equation below: 
 
𝑦(𝑡) = 	' 𝐴[𝑖]exp	{− 𝑡𝜏[𝑖]234567 } + 𝐵𝑘𝑔𝑟	 
Equation 1 
Where: n = number of exponentials (n ≤ 2 for 
all cases depending on goodness of fit); A = 
amplitudes; 𝜏 = lifetimes; Bkgr = correction for 
background (after-pulsing, dark counts, 
environmental light).  
Spectroscopy data were fit to mono- or bi-
exponential decay fits (depending on goodness 
of fit). For cell images, raw decay data from all 
cellular pixels were fit to bi-exponential models 
and this method was used to generate the 
corresponding lifetime images.  
For cell compartment specific analyses, 
nuclear, perinuclear and extra-perinuclear 
regions of interest (ROIs) were drawn to 
achieve 1000 or more counts to ensure effective 
bi-exponential decay analysis. Bi-exponential 
tail fit was used to fit decays from each ROI and 
individual components (lifetime and amplitude) 
were obtained. Good χ2 values (0.8-1.2) and 
random distribution of x-axis residuals were 
considered necessary for an accurate decay fit. 
Amplitude average fluorescence lifetimes (τamp) 
were calculated and reported using the 
following model and reported as average 
lifetime values.  
 		𝜏>?@ = '𝐴[𝑘]𝜏[𝑘]234A67 '𝐴[𝑘]234A67B  
Equation 2 
Analyzed data was plotted using Prism 
(Graphpad, La Jolla, CA). Wherever required, 
appropriate statistical analysis was performed 
using Prism’s built-in functions and 
corresponding p values were reported. 
Super-resolution imaging and data 
analysis 
Single-molecule super-resolution imaging 
was used to image the binding and cellular 
uptake of individual prodrug molecules. First, 
images of individual fluorescent molecules 
with switchable bright-dark states (blinking) 
were captured, and their positions were 
measured by fitting each blinking event to a 
two-dimensional Gaussian function. A super-
resolved image was then reconstructed by 
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combining all positions from the stochastic 
blinking events of fluorescent molecules. To 
resolve the fluorescence signal from a single 
molecule, a bright fluorophore, AlexaFluorÔ 
488 (AF488), was used and conjugated to the 
phospholipid at the Sn-2 position as the prodrug 
analog for super-resolution imaging.  AF488-
PD was more photostable than DOX-PD and 
permitted detection of single copies of AF488-
PD in the presence of autofluorescence, 
extending SRM tracking time and improving 
estimates of molecular migration patterns and 
prodrug membrane retention. Freely-diffusing 
AF488-PD in the extracellular buffer and in the 
cytosol were not captured, since their quickly-
moving fluorescence signals were out of focus 
and/or averaged out by the detector. However, 
when AF488-PD temporarily docked onto the 
lipid membrane, its slowed diffusion was 
captured and localized from which a super-
resolution image was reconstructed with spatial 
resolution beyond refraction limit. In this way, 
single-molecule super-resolution imaging 
precisely localized the prodrug molecules with 
single-molecule sensitivity.  
Super-resolution imaging was performed on a 
home-built microscope equipped with a 100X 
oil immersion objective (Figure S2) [30, 31]. 
After AF488-PD incubation, the cells were 
washed with PBS to remove the excess prodrug 
in the media. Cells were first illuminated with a 
488-nm laser (OBIS, Coherent) at a peak 
intensity of 0.12 kW⁄cm2 at the sample. The 
images were filtered with a 523/610 dual-band 
bandpass filter (Semrock FF01-523/610) and 
acquired by a sCMOS camera (Hamamatsu, 
C11440-22CU) with a 50 ms exposure time. 
Next, merocyanine 540 (MC540, Invitrogen) 
was introduced to cell media to image the cell 
membranes via PAINT (Point Accumulation 
for Imaging in Nanoscale Topography) [32]. 
Similar to AF488-PD, localizations were only 
acquired when MC540 temporarily docked 
with the cell membranes and emitted bright 
fluorescence, thereby enabling the co-
localization of prodrug molecules relative to 
cell membrane with nanoscale resolution. 
MC540 was excited with a 561-nm laser 
(Sapphire, Coherent) at a peak intensity of 2.7 
kW⁄cm2 at the sample, and images were 
acquired with a 50 ms exposure time. The 
single AF488-PD and MC540 molecules were 
identified and localized by two-dimensional 
Gaussian fitting using an ImageJ plug-in 
ThunderSTORM [33].  
The super-resolution images of prodrug and 
cell membranes consist of the sum of all 
localizations from AF488-PD and MC540 
respectively, binned as a 2D histogram with bin 
size 58.5×58.5 nm2. AF488-PD localizations 
over time were grouped into a trajectory when 
present in consecutive frames (up to a 3-frame 
gap) within a distance of 0.59 μm. The 
trajectories were plotted using custom software 
(MATLAB, MathWorks). No trajectory 
analysis was performed for the endothelial 
filopodia. 
 
Results 
Spectroscopic characterization of 
synthesized prodrugs 
Absorption and fluorescence spectra and 
decay characteristics of the materials were 
measured in a water solution. DOX and DOX-
PD had similar absorption spectra (Figure 1A). 
The spectra for αvβ3-DOX-PD PFOB NP was 
obscured by light scattering.  
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Figure 1. Spectroscopic characterization of doxorubicin (DOX), doxorubicin prodrug (DOX PD), and αvβ3-integrin 
targeted prodrug nanoparticles (αvβ3-DOX-PD PFOB-NPs) in water:  Absorption spectra of the materials (A). The absorption 
of doxorubicin prodrug in nanoparticle formulation is obscured by light scattering. Presence of doxorubicin is confirmed in 
the corresponding fluorescence emission (B).  Fluorescence decay characteristics of the materials (C). DOX decay can fit to 
mono-exponential decay of 1.09 ± 0.02 ns. DOX-PD can fit to bi-exponential decay with τa = 1.21 ns (47%); τb = 0.69 ns 
(53%). DOX-PD NP can fit to bi-exponential decay with τa = 3.78 ns (22%); τb = 1.34 ns (78%). Data represent mean ± sd, 
n=3 measurements. IRF – Instrument response function. 
 
All drug formulations showed similar 
fluorescence emission spectra, which 
corroborated the presence of doxorubicin in the 
nanoparticles (Figure 1B). The emission peak at 
~556 nm for doxorubicin in the αvβ3-DOX 
PFOB NP was relatively more prominent. This 
observation may reflect the unique interactions 
of the doxorubicin molecules with the core 
PFOB molecules that penetrate to the particle-
water interface [34].   
 As shown in Figure 1C, free DOX 
fluorescence fit a mono-exponential decay of 
1.09 ± 0.02 ns (χ2 = 1.06), consistent with 
literature findings. DOX-PD decay best fit a bi-
exponential decay model with nearly equal 
contributions from a fast lifetime component τa 
= 0.69 ± 0.06 ns (53%) and a slow lifetime 
component of τb = 1.21 ± 0.03 ns (47%), 
indicative of a heterogeneous system (χ2 = 
1.007). The amplitude average lifetime (τamp) 
was calculated to be 0.96 ± 0.04 ns. Dynamic 
light scattering analysis of a DOX-PD in water 
revealed a mixed suspension of free prodrug 
molecules and spontaneously formed prodrug 
micelle aggregates (~1600 nm).  Fluorescence 
lifetime of doxorubicin bound to biological 
molecules (lipid membranes, DNA) and while 
encapsulated in nanoparticles increases as the 
molecules are shielded from external 
fluorescence quenchers and by p-p stacking 
[35-38].  Hence, the slower lifetime component 
from DOX-PD suspension was attributed to the 
micellar fraction of the drug distribution where 
the anthracycline portion of DOX-PD was 
shielded from surrounding water molecules. 
The faster lifetime of 0.69 ns can be attributed 
to the free DOX-PD molecules in water. This 
value is slightly different than that of free DOX 
in water, reflecting the effect of drug 
conjugation with the lipid molecule.  
Fluorescence decay of αvβ3-DOX-PD PFOB 
NP fit a double exponential decay model with 
components τa = 3.78 ± 0.03 ns (22%) and τb = 
1.34 ns (78%) (χ2 = 1.03). The majority of the 
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αvβ3-DOX-PD PFOB NP had the faster 
fluorescence lifetime component (1.34 ns) 
similar to that of DOX-PD in the micellar 
fraction (1.21), indicating similar hydrophobic 
interactions. The slower lifetime fractional 
component (3.78 ns) is likely related to 
hydrophobic interactions of DOX-PD within 
the nanoparticle lipid surfactant intercalated 
between PFOB molecules.   
Cellular uptake and cytotoxicity of αvβ3-
DOX-PD PFOB NP 
The cellular distribution of DOX presented as 
the free drug and delivered within nanoparticle 
surfactant in prodrug form was observed with 
fluorescence microscopy (Figure 2). 
 
 
Figure 2. Cellular internalization and cytotoxic effects of αvβ3-DOX-PD PFOB-NP: Internalization of DOX and αvβ3-
DOX-PD PFOB-NP in 2F2B cells incubated with reagents for 30 min. Red shows doxorubicin fluorescence signal and blue 
is nuclear counterstain, overlay is purple. (A) 2F2B cells treated with free DOX showing most red signal localized into nucleus 
(white arrow). (B) 2F2B cells treated with αvβ3-DOX-PD PFOB-NP showing signal diffuse through cytosol, membrane 
(yellow arrow) and nucleus (white arrow).  (C) MTT cytotoxicity assay after 48 h of treatment, showing αvβ3-DOX-PD PFOB-
NP was significantly more cytotoxic than the equivalent dose of free DOX (p<0.05) while drug-free NP had no effect on cell 
proliferation. Statistical analysis was performed using unpaired Student's T test and p values were assigned. 
 
Benign 2F2B mouse endothelial cells were 
exposed to DOX and αvβ3-DOX-PD PFOB NP. 
Free DOX internalized and localized rapidly to 
cell nuclei within 30 min of treatment with 
negligible cytosolic retention noted (Figure 
2A). DOX-PD delivered by αvβ3-targeted NP 
bound to the cell membrane periphery, entered 
the cell via the CFDD mechanism and rapidly 
dispersed into the cytosol membranes. Lipase-
released DOX was observed in the nucleus 
(Figure 2B). Circumventing cell internalization 
with endosome sequestration and escape, a 
common pathway for nanoparticle drug 
delivery, DOX-PD dispersed throughout the 
cytoplasmic membrane. Enzymatically 
liberated DOX accumulated in the nucleus.  
The cytotoxic bioactivity of αvβ3-targeted 
DOX-PD PFOB NP referenced to equimolar 
free DOX was assessed in 2F2B mouse 
endothelial cells stimulated with angiotensin II 
using the MTT cytotoxicity assay. The control 
αvβ3-no-drug NP had no impact on cell 
proliferation (Figure 2C).  Both free DOX 
added to the media and αvβ3-DOX-PD PFOB 
NP were cytotoxic (Figure 2C). At 48 h αvβ3-
DOX-PD PFOB NP decreased cell proliferation 
by 44% (P<0.01) as compared to the control 
αvβ3-no-drug NP. An equivalent dose of free 
DOX decreased cell proliferation by 19% 
(P<0.05) compared to the control. The αvβ3-
DOX-PD PFOB NP was significantly more 
toxic than equivalent amounts of free DOX 
(P<0.05). These data showed that the Sn-2 
coupling of DOX to the phosphatidylcholine 
lipid backbone did not compromise drug net 
bioactivity and suggested that continued 
liberation of DOX from the DOX-PD reservoir 
retained in the cytoplasm over 48 hours 
contributed to effectiveness.   
Temperature dependent cellular uptake 
of αvβ3-DOX-PD PFOB NP 
Fluorescence imaging of prodrug trafficking 
performed in normal proliferating endothelial 
cells was reflective of previous anti-
angiogenesis experiments [10, 12, 39, 40] with 
Sn-2 prodrugs. As opposed to normal 
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proliferating endothelial cells, the next 
experiments explored Sn-2 prodrug behavior in 
abnormal human C-32 melanoma.  
Drug uptake from αvβ3-DOX-PD PFOB NP 
was studied in cultured C-32 cells at 37 °C and 
at 4 °C, the later to induce cold suppression of 
ATP-dependent mechanisms (Figure 3).  
 
 
Figure 3. Effect of temperature on cellular uptake of αvβ3-DOX-PD PFOB-NP: Comparison of cellular uptake of αvβ3-
DOX-PD PFOB-NP after 1 h incubation at 37 degrees (A) and 4 degrees C (B). Control untreated cells show near zero signal 
(C). Quantified background corrected whole cell fluorescence (mean ± sem, n=5 cells for each of the 3 independent 
experiments) showing internalization is reduced at 4 degrees C (D). 
 
 
DOX-PD transfer from the bound 
nanoparticle surfactant to the outer cell 
membrane leaflets was similar under both 
temperature regimens.  While transfer of DOX-
PD from the outer to inner cell membrane 
leaflets was rapid and unimpaired at 37 °C, at 4 
°C DOX-PD delivery to the inner leaflet and 
contiguous intracellular membranes was 
reduced but notably present well-above 
background fluorescence. This was in 
contradistinction to previous studies using 
rhodamine-PE as a drug surrogate in which 
translocation of the fluorescent lipid from the 
outer to inner cell membrane leaflets was 
blocked at 4 °C. These data suggest that DOX-
PD and other PC-PD will translocate between 
membrane leaflets by ATP-dependent and 
ATP-independent mechanisms and slowly 
diffuse into cells in the absence of energy. 
Pixel-by-pixel fit of the raw decay data shows 
gradient of amplitude average lifetime τamp 
throughout the cells (Figure 4B). Untreated 
cells showed minimal background signal under 
these imaging conditions (Figure S4). We 
performed cell compartment specific analysis 
of our lifetime data as below (Figure S5). 
 
Nucleus 
Nuclei of cells treated with DOX and αvβ3-
DOX-PD PFOB-NPs showed similar lifetime 
distribution suggesting that DOX liberated 
from lipid prodrug retained the same dsDNA 
binding character as the native compound 
(Figure S3). Previous studies have reported 
DOX bound to dsDNA exhibits higher lifetime 
(2.2 ns – 1.3 ns, [37, 38, 41]). Upon fitting 
decays from nuclear ROIs using bi-exponential 
model, a major component of fast lifetime 1.44 
ns ± 0.06 ns (80% ± 4%, n=52) was detected 
reflecting dsDNA-bound DOX.  A minor slow 
lifetime component (3.80 ± 0.24 ns) in the 
nucleus was attributed to noise from 
backscattering of excitation light and auto-
fluorescence, which was also noted for 
untreated cells (Figure S4). τamp in the nuclei 
decreased steadily between 1 h (2.11 ± 0.04 ns) 
and 8 h (1.82 ± 0.02) post-incubation (Figure 
4C, P<0.001). This observation was previously 
observed by others and attributed to drug-
induced apoptosis with consequent remodeling 
of chromatin network in the nucleus [41].   
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Figure 4. Fluorescence lifetime imaging of C-32 cells treated with αvβ3-DOX-PD PFOB-NP. Fluorescence intensity images 
of C-32 cells with αvβ3-DOX-PD PFOB-NP for 1, 4, 8, and 24 h, showing doxorubicin fluorescence from cell cytoplasm and 
nucleus at all time points. A perinuclear space with high signal intensity is observed in all cells (red arrows) indicating 
accumulation of drug (A). Corresponding fluorescence lifetime images generated by pixel-by-pixel fitting of decay data show 
a gradient of τamp in different cell compartments (B). Quantification of τamp from nuclear compartments shows time dependent 
decrease (n= 7-18 cell nuclei at each time point, 3 independent experiments, p<0.001) suggested drug induced apoptosis (C). 
Percentage contributions of slow and fast components in the bright perinuclear region (τamp = 1.8 ± 0.2 ns) compared to the 
rest of the cytosol ((τamp = 2.9 ± 0.3 ns)) for cells treated with αvβ3-DOX-PD PFOB-NP for 8 h (D). Bright perinuclear ROIs 
show greater contribution of fast lifetime than cytosolic regions outside it (mean ± sem, n= 15 cell ROI measurements). 
Statistical analysis was performed using unpaired Student's T test and statistical significance was assigned for p<0.001, 
represented by ***. 
 
Cytoplasm 
 The cytoplasm of cells treated with αvβ3-
DOX-PD PFOB-NPs demonstrated fluores-
cence signal at all time points with consistently 
high signal noted in the perinuclear space 
(Figure 4A, red arrows). This region coincides 
with the location of Golgi/ER, which is 
associated with enriched levels of cytosolic 
phospholipase A2 (cPLA2) activity [42]. 
Comparisons within and outside the bright 
perinuclear regions showed lower τamp (1.8 ns 
± 0.2 ns, n=15 ROI) in the perinuclear regions 
than the later (τamp = 2.9 ns ± 0.3 ns, n=15 ROI). 
The lower τamp observed in bright perinuclear 
region was due to greater contribution from a 
faster lifetime component (1.1 ns, 82% ± 3%) 
suggesting an abundance of free DOX 
molecules. In the surrounding cytosol, this 
faster component was much less in proportion 
(1.06 ns, 52% ± 8%), indicating lower amounts 
of free DOX (Figure 4D). The slower lifetime 
components from both perinuclear and 
surrounding regions was attributed to a 
combination of background (as observed in cell 
nuclei) and from bound drug (as observed in 
literature and our spectroscopic studies). By 
extension, the collective data suggested that 
phospholipase release of Sn-2-linked 
doxorubicin from the PC backbone was more 
concentrated in the perinuclear region than in 
the general cytosol. 
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Super-resolution microscopy of cellular 
binding and internalization of prodrug 
molecules 
Single-molecule super-resolution microscopy 
(SRM) captures images of fluorescent 
molecules with nanometer resolution beyond 
the optical diffraction limit. The AF488-PD, 
which contains fluorescent AF488 molecules 
conjugated to the phospholipid at the Sn-2 
position, preferentially intercalated into the 
outer membrane leaflet of cells.  
 
 
 
Figure 5. Early-stage binding of AF488-PD on the membrane and internalization in 2F2B cells. (A) Bright-field and super-
resolution images of AF488-PD (red, after 5 min incubation) and cell membrane probe MC540 (green) on the membrane of 
a 2F2B cell. The overlay images are focused at different heights above the coverslip. The arrows indicate the colocalized 
active binding sites of AF488-PD and MC540 on the membrane. (B) Both transient binding and diffusion (trajectories on the 
right part of the image) of single AF488-PD molecules were observed on the cell membrane after 5 min incubation. 
Trajectories on the filopodia were not shown. Magnified views of the boxed regions shown in insets: (i) scatter plot of single 
AF488-PD molecules (red) binding to filopodia, (ii, iii) representative trajectories of single AF488-PD molecule diffusing on 
the cell membrane with the total length of 3.50 s and 1.65 s, respectively; color-coded for time. (C) Fluorescence images of 
AF488-PD (red) after a 12-hour incubation at different heights above the coverslip, showing intracellular accumulation of 
the prodrug. PAINT images of MC540 (green) indicate the contour of the cell membrane. CS, coverslip; MEM, membrane; 
CY, cytoplasm; NU, nucleus. 
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In 2F2B endothelial cells, AF488-PD (Figure 
5A, red) was imaged within the cell membrane 
after 5 min of incubation, co-localizing with 
another membrane marker dye, MC540 (Figure 
5A, green). As noted in the bright field images 
shown in Figure 5A, SRM of AF488-PD and 
MC540 both accumulated in the outer cell 
membrane at different z heights (1, 2, 3 μm) 
above the coverslip. These merged PAINT 
images suggested that the PC prodrug 
inherently incorporated into the cell membrane 
with little spatial restriction between the base of 
the cell on the coverslip and the apical surface 
fully exposed to the bulk media. In addition to 
the primary cell body surface membrane, 
AF488-PD also incorporated into 2F2B cell 
filopodia processes as noted in the magnified 
image of the box (i) in Figure 5B. In 
contradistinction, standard epifluorescence 
microscopy imaging showed that the PE-
rhodamine did not broadly intercalate into the 
outer phospholipid cell membrane but was 
primarily associated with the cell along the 
coverslip region where cell adherent molecules 
are highly expressed and engaged (Figure S6). 
This observation was consistent with the report 
of Partlow et al, which associated PE-
rhodamine uptake with specific lipid-raft 
membrane regions [4].  
The diffusion of single molecules of AF488-
PD through the cytosol was imaged using 
single-molecule fluorescence imaging 
(Supplementary video S1). The trajectories 
shown in Figure 5B illustrated the trackable 
paths of single prodrug molecules prior to 
photobleaching, diffusion beyond the focal 
plane of the microscope, or enzymatic dye 
liberation into the cytosol. Two representative 
trajectories are presented in the magnified 
images, box (ii) and (iii), in Figure 5B. 
Individual freely-diffusing prodrug molecules 
were also observed at the coverslip level of the 
cell, which likely reflected the rapid mobility of 
cell membrane phospholipid constituents [43]. 
With longer incubation times at 37 °C more 
AF488-PD entered the membrane from the 
media and internalized into the cell. Figure 5C 
shows the fluorescence images of 2F2B cells 
after incubation with AF488-PD for 12 h. At 
this stage, AF488 fluorophores accumulated 
broadly within the internal cell membranes 
particularly in the perinuclear region, 
corroborating the fluorescence microscopy 
observation. Fluorescence images obtained at 
different z heights (Figure 5C at 0.5, 2.5, 6.5 μm 
above the coverslip) showed dye throughout the 
cell with the intensity of the light signal 
proportional to the proximity of AF488-PD to 
the microscope’s focal plane, while the 
autofluorescence background from 2F2B cells 
was low (Figure S7). Diffuse red signal 
associated with AF488-PD was noted beyond 
the microscope’s depth of field. The rapid 
motion of freely diffusing liberated AF488 
molecules were not resolved in the cytoplasm 
(Figure 5C). 
Discussion 
In vivo efficacy of Sn-2 PC prodrugs 
incorporated into the surfactant of lipid-
encapsulated nanoparticles has been 
demonstrated previously [9-12].  These studies 
showed that the Sn-2 PC PD motif inhibited 
significant premature drug loss and drug 
metabolism during circulation to the targeted 
pathology. However, evidence corroborating 
prodrug avoidance of internalization and 
sequestration within the endosome/lysosome 
pathway versus CFDD-mediated translocation 
into intracellular membrane distribution with 
subsequent enzymatic drug liberation was 
lacking.  In the present series of experiments, 
PC prodrug delivery into cells and intracellular 
trafficking was investigated using three 
complementary optical imaging methods: 
classic fluorescence microscopy, fluorescence 
lifetime imaging microscopy, and single-
molecule super-resolution microscopy. The 
overarching result suggests that the PC 
prodrugs act as mimics of phosphatidylcholine 
with regard to cell membrane uptake, 
membrane leaflet translocation, intracellular 
distribution, and enzymatic metabolism in 
normal and cancerous cell lines.   
In prior research with rhodamine-PE as a lipid 
drug surrogate in αvβ3-targeted lipid-
encapsulated NP, access into cells was confined 
to lipid rafts and transfer of the fluorescent PE 
from the outer to inner cell membrane leaflets 
was dependent on ATP, consistent with the a 
well-known amino-phospholipid flippase 
transport protein mechanism. In ATP-starved 
situations, such as hypoxic cancer cells, 
targeted delivery of PE-based prodrugs could 
be compromised. In contradistinction, PC-
prodrugs intercalated throughout the outer cell 
membrane leaflet, including filopodia 
processes and translocated to the inner leaflet 
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rapidly at 37 °C.  ATP-suppressing cold 
treatment (4 °C) partially inhibited the outer to 
inner membrane leaflet translocation of PC-
prodrug, but substantial drug transferred into 
the inner leaflet and then migrated throughout 
the cytosolic membranes. These data suggest 
that DOX-PD and other PC-PD will translocate 
between membrane leaflets by ATP-dependent 
and ATP-independent mechanisms and slowly 
diffuse into cells in the absence of energy.  
Moreover, spatially unrestricted cell entry 
combined with ATP independent translocation 
into the cell are both favorable for drug 
delivery. 
PC prodrugs broadly disseminated into 
cytosolic membranes overtime, but a 
significant intracellular trajectory was noted in 
the lipid membranes of vesicles, likely 
endosomes, trafficking toward the perinuclear 
nuclear Golgi/ER region, a pathway well-
documented for native PC [26].  The 
perinuclear Golgi/ER region has enriched 
concentrations of cytoplasmic phospholipase 
A2, a lipase involved in the degradation and 
recycling of phosphatidylcholine [42, 44].  
Enhanced local perinuclear enzymatic 
liberation was demonstrated with doxorubicin 
Sn-2 prodrug (DOX-PD) and fluorescence 
lifetime microscopy. In perinuclear Golgi/ER 
region, increased concentrations of free 
doxorubicin were estimated. In other 
cytoplasmic membrane regions with prevalent 
DOX-PD retention, substantially lower 
concentrations of released drug were estimated.   
Fluorescence lifetime imaging further 
demonstrated that the PC-released doxorubicin 
entered the nucleus and bound to dsDNA 
similar to native doxorubicin. In culture, free 
doxorubicin entered cells rapidly and localized 
to the nucleus with negligible cytoplasm 
retention.  By comparison, DOX-PD entered 
the cell after NP targeting and a visually 
significant portion of the drug rapidly bound 
within the nucleus. However, unlike free DOX, 
less drug was observed in the nucleus and a 
significant proportion of the prodrug remained 
within the cytoplasmic membranes. 
Nevertheless, the biopotency of the native and 
prodrugs were at least equivalent with regard to 
cell proliferation when measured by MTT assay 
at 48 hours.  If the drug cytotoxicity is directly 
correlated to the compound bound to dsDNA, 
then the residual prodrug within the 
intracellular membrane may have constituted a 
slower release depot with continued drug 
liberated over the 48-hour experiment 
increasing nuclear DOX delivery.  
Alternatively, the slower translocation of DOX-
PD to the nucleus with residual cytoplasm 
retention may have increased the 
antiproliferative contributions of other 
pathways of doxorubicin toxicity, such as in the 
mitochondria [45].  
In the present study, definitive confirmation 
of PC-PD migration to the Golgi, specifically, 
was not established and tracking to the 
endoplasmic reticulum or both organelles in the 
perinuclear region could not be differentiated.   
Additionally, the potential role of doxorubicin 
exocytosis when delivered as the prodrug 
versus free drug form was not studied. 
Attention was placed on the binding of liberated 
DOX to DNA over time, which evolved slowly 
from the retained cytosol membrane depot. 
Finally, the MTT assay was used to assess cell 
apoptosis. Although careful washing of residual 
doxorubicin prior to the addition of assay 
reagents to the cell culture was performed, a 
complementary caspase assay might 
additionally inform whether the treated cells 
cycled into apoptosis versus the control. 
 
Conclusion 
 Sn-2 lipase labile phospholipid prodrugs in combination with the contact-facilitated drug 
delivery mechanism have been demonstrated for targeted nanoparticle therapy in vivo. In this report, 
traditional fluorescence microscopy, fluorescence lifetime imaging, and single-molecule super-
resolution imaging techniques were used to elucidate the intracellular trafficking and metabolism details 
of PC prodrugs for the first time. PC prodrugs incorporated broadly into the outer cell membrane leaflet 
over the cell body and filopodia, and translocated to the inner membrane leaflet by ATP-dependent and 
ATP-independent mechanisms. Nanoparticles were not sequestered into endosomal vesicles, but the PC 
prodrugs delivered into the cells populated vesicle membranes that trafficked to the perinuclear 
Golgi/ER region as well as distributed through the intracellular membranes in the cytosol.  As an 
example, doxorubicin-prodrug tracked to the Golgi/ER region where the highest level of liberated drug 
was measured compared to the general cytosol. The released anthracycline displayed similar 
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fluorescence lifetimes when bound to dsDNA as the native.  In contradistinction to free doxorubicin, 
which transferred directly to the nucleus after cell uptake, a significant portion of DOX-PD remained 
within cytosolic membranes. Nevertheless, the biopotency of the native and prodrugs were at least 
equivalent with regard to cell proliferation at 48 h, which suggests that the retained DOX-PD may have 
constituted a prolonged release reservoir that enhanced effectiveness over two days. While the specific 
fluorescence lifetimes measured in the present study have limited relationship with values for in vivo 
imaging, this study provided the first evidence-based understanding of intracellular Sn-2 PC prodrug 
fate. 
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Video S1. Video clip showing the single-molecule fluorescence images of AF488-PD molecules on a 
2F2B cell within the same field of view as in Figure 5B in the main text. The trajectory from 0.55 to 
4.00 s indicates the diffusive path of a single AF488-PD molecule on the cell membrane (see also, 
Figure 5B, inset (ii) in the main text). 
 
 
